Investigational drug · Phase 3
Raphamin
Also called: MMH-407
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Rhinosinusitis, Rhinosinusitis Acute, Cystitis Chronic.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
4 still active
All registered trials
9
Any phase or sponsor naming "Raphamin"
First trial start
2023
Oct 16, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Raphamin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Rhinosinusitis
- Rhinosinusitis Acute
- Cystitis Chronic
- Cystitis Bacterial
- Recurrence of Chronic Bacterial Cystitis
- Bronchitis
- Acute Bronchitis
- Acute Respiratory Viral Infection
- Community-acquired Pneumonia
- Pneumonia
Approved drugs for the same conditions: Pneumonia · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Raphamin" as an intervention, largest first.
- Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in OutpatientsPivotal-lookingCompleted
Materia Medica HoldingIndustry
NCT05364671 · 771 participants · Start Apr 29, 2022 · Primary completion Aug 18, 2023
Drug: Raphamin; Placebo · For: Coronavirus Disease 2019 (COVID-19)
Sites: Belgorod, Russia; Ivanovo, Russia; Kazan', Russia · 36 sites in all
- The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult PatientsPivotal-lookingRecruiting
Materia Medica HoldingIndustry
NCT06901297 · 552 participants (planned) · Start Apr 3, 2025 · Primary completion Dec 31, 2027
Drug: Raphamin; Placebo · For: Rhinosinusitis; Rhinosinusitis Acute
Sites: Aramil, Russia; Gatchina, Russia; Kaliningrad, Russia · 44 sites in all
- Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years OldPivotal-lookingCompleted
Materia Medica HoldingIndustry
NCT04918771 · 435 participants · Start Apr 29, 2021 · Primary completion Jul 21, 2023
Drug: Raphamin; Placebo · For: Acute Respiratory Viral Infection
Sites: Kazan', Russia; Krasnodar, Russia; Moscow, Russia · 29 sites in all
- Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial CystitisPivotal-lookingActive, not recruiting
Materia Medica HoldingIndustry
NCT06284265 · 415 participants · Start Oct 16, 2023 · Primary completion Dec 31, 2026
Drug: Raphamin; Placebo · For: Cystitis Chronic; Cystitis Bacterial; Recurrence of Chronic Bacterial Cystitis
Sites: Irkutsk, Russia; Kazan', Russia; Kemerovo, Russia · 49 sites in all
- Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 YearsPivotal-lookingRecruiting
Materia Medica HoldingIndustry
NCT06715891 · 374 participants (planned) · Start Nov 11, 2024 · Primary completion Dec 31, 2027
Drug: Raphamin; Placebo · For: Acute Respiratory Viral Infection
Sites: Gatchina, Russia; Kazan', Russia; Krasnodar, Russia · 35 sites in all
- Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired PneumoniaPivotal-lookingCompleted
Materia Medica HoldingIndustry
NCT06263881 · 370 participants · Start Dec 1, 2023 · Primary completion Mar 19, 2025
Drug: Raphamin; Placebo · For: Community-acquired Pneumonia; Pneumonia
Sites: Aramil, Russia; Arkhangelsk, Russia; Gatchina, Russia · 38 sites in all
- Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient AdultsPivotal-lookingSuspended
Materia Medica HoldingIndustry
NCT04250311 · 314 participants (planned) · Start Dec 12, 2019 · Primary completion Dec 2024
Drug: MMH-407; Placebo · For: Influenza
Sites: Barnaul, Russia; Belgorod, Russia; Chelyabinsk, Russia · 20 sites in all
- Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of Acute Bronchitis in Adult PatientsPivotal-lookingRecruiting
Materia Medica HoldingIndustry
NCT07650227 · 308 participants (planned) · Start Dec 9, 2025 · Primary completion Dec 31, 2028
Drug: Raphamin; Placebo · For: Bronchitis; Acute Bronchitis
Sites: Aramil, Russia; Gatchina, Russia; Izhevsk, Russia · 33 sites in all
- Clinical Trial of Efficacy and Safety of ММН-407 in Acute Respiratory Viral InfectionPivotal-lookingCompleted
Materia Medica HoldingIndustry
NCT04244084 · 240 participants · Start Oct 8, 2019 · Primary completion Apr 9, 2020
Drug: MMH-407; Placebo · For: Viral Respiratory Infection
Sites: Barnaul, Russia; Belgorod, Russia; Chelyabinsk, Russia · 26 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- [The effect of etiopathogenetic therapy of COVID-19 on the severity of the disease: results of a multicenter double-blind placebo-controlled randomized trial].
Nikiforov VV, Petrov VA, Stremoukhov AA, et al. · Ter Arkh 2023
- Efficacy of Raphamin against Pneumococcal Infection: a Preclinical Study.
Petrova NV, Emelyanova AG, Tarasov SA, et al. · Bull Exp Biol Med 2023
- Antiviral Activity of Technologically Processed Antibodies to CD4 Receptor against Influenza Infection.
Petrova NV, Emelyanova AG, Tarasov SA, et al. · Bull Exp Biol Med 2022
- [Evaluation of the efficacy and safety of a complex antiviral drug based on antibodies in the treatment of adult patients with acute respiratory viral infection].
Khamitov RF, Nikiforov VV, Zaytsev AA, et al. · Ter Arkh 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.